Background. With use of peginterferon alfa-2a and ribavirin combination therapy in patients with dual chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 11.2% of patients achieved ...
(RTTNews) - Vir Biotechnology Inc. (VIR) announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus or ...
Please provide your email address to receive an email when new articles are posted on . The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran plus an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results